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Background. Little is known about the incidence of inadequate treatment of severe Staphylococcus aureus infection
in Europe. We aimed to evaluate the adequacy of antibiotic therapy for S. aureus bacteremia (SAB), to identify
determinants of inadequate treatment, and to determine the effect of inadequate treatment on patient outcome in a
representative selection of hospitals in 9 Western European countries.
Methods. In this retrospective cohort study, all adult patients with SAB (due to methicillin-susceptible S. aureus
[MSSA] or methicillin-resistant S. aureus [MRSA]) who were admitted to 60 randomly selected hospitals from 1
November 2007 through 31 December 2007 were included. Adequate antimicrobial therapy was defined as intravenous
administration of at least 1 antibiotic to which the isolate showed in vitro susceptibility that was initiated within 2
days after onset of SAB.
Results. A total of 334 SAB episodes (257 due to MSSA and 77 due to MRSA) were included. Ninety-four patients
(28%) received inadequate empirical therapy (21% in the MSSA group and 52% in the MRSA group). Both length
of stay before SAB onset and methicillin-resistant infection were associated with inadequate therapy, with adjusted
odds ratios (ORs) of 1.01 (95% confidence interval [CI], 1.00–1.03) and 3.7 (95% CI, 2.2–6.4), respectively. Age
(OR, 1.06; 95% CI, 1.03–1.10), Charlson comorbidity score (OR, 2.1; 95% CI, 1.2–3.6), severe sepsis or septic shock
(OR, 2.7; 95% CI, 1.5–4.8), and intensive care unit stay at onset of SAB (OR, 2.9; 95% CI, 1.5–5.6) but not inadequate
treatment (OR, 0.7; 95% CI, 0.4–1.3) were associated with increased 30-day mortality.
Conclusion. Inadequate empirical antimicrobial therapy for SAB is common in Western Europe and is strongly
associated with infection caused by MRSA. In this study, inadequate treatment was not associated with increased 30-
day mortality rates.
Staphylococcus aureus is responsible for 10%–18% of all
community-acquired and ∼20% of all nosocomial bac-
teremias [1, 2], thereby representing a significant burden
on health care services [3]. Incidences of both com-
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munity-acquired and nosocomial S. aureus bacteremia
(SAB) have increased during recent decades, probably
because of an increasing population at risk [4–6]. In
addition, methicillin-resistant S. aureus (MRSA) has be-
come endemic in the hospitals of most European coun-
tries, which may also add to the total burden of SAB
[7]. Reported crude hospital mortality rates among
adult patients with SAB have ranged from 18% to 46%
[2, 8, 9]. Increased mortality rates have been associated
with a respiratory source of SAB or unknown primary
infection, presence of shock, older age, male sex, and
severity of underlying disease [10–13]. Increasing in-
cidences of MRSA infection confront physicians with
998 • CID 2009:49 (1 October) • Ammerlaan et al
Table 1. Complete List of Empirical Antibiotic
Regimens Prescribed for 334 Patients with
Staphylococcus aureus Bacteremia
This table is available in its entirety in
the online version of Clinical Infectious Diseases
Figure 1. Results of hospital recruitment. SAB, Staphylococcus aureus
bacteremia.
increasing difficulties in empirical treatment decisions [14]. The
consequences of inadequate therapy include longer hospital
stay, higher health care–associated costs, and even higher mor-
tality rates [15–19], although this last association has not been
found in some recent studies [20–22].
Little is known about the incidence of and outcomes asso-
ciated with inadequate treatment of severe S. aureus infection
in Western Europe. Our primary aim was, therefore, to deter-
mine the occurrence of inadequate empirical treatment among
hospitalized patients with SAB in a representative sample of
hospitals in 9 Western European countries. Secondary objec-
tives were to determine associations between hospital-specific,
patient-specific, and microorganism-specific characteristics and
inadequate treatment of SAB and 30-day mortality rates.
MATERIALS AND METHODS
Study design, study setting, and study population. We per-
formed a retrospective cohort study of patients with micro-
biologically confirmed SAB from 1 November 2007 through
31 December 2007 with in-hospital follow-up of 30 days. A
randomized sample frame was created from a complete list of
general and teaching hospitals in Denmark, France, Germany,
Italy, the Netherlands, Spain, Sweden, Switzerland, and the
United Kingdom. The hospitals were approached in consecutive
order of the sample frame. Hospitals were deemed to be in-
eligible if they had had no SAB episodes during the surveil-
lance period, were a pediatric or psychiatric hospital, or had
!50 beds.
Eligible patients were those 18 years of age who were hos-
pitalized with SAB in any of the randomly selected hospitals
(community-acquired SAB) or who acquired SAB during hos-
pitalization (hospital-acquired SAB) during the study period.
The following patients were excluded: those with SAB as part
of a polymicrobial bacteremia, those in whom the antimicrobial
susceptibility pattern (methicillin-susceptible S. aureus [MSSA]
or MRSA) of S. aureus was unknown, those already receiving
adequate antimicrobial therapy before the index blood culture
was obtained, and those who died within 1 day after the index
blood culture was obtained. Identification of S. aureus and
determination of antibiotic susceptibilities were performed ac-
cording to local guidelines and procedures.
Institutional review boards of participating hospitals were
informed if deemed necessary by the local investigator. In most
hospitals, a formal protocol review was not required, because
the study did not influence standard care, and because data
collection was completely anonymous. The Danish Data Pro-
tection Agency approved participation of Danish hospitals.
Data collection and variables of interest. Empirical ther-
apy was defined as all antimicrobial agents administered be-
tween the time that the index blood culture was obtained and
the receipt of the final blood culture result (ie, identification
of S. aureus and its antimicrobial susceptibility pattern) (Table
1). Definitive therapy was defined as all antibiotic therapy ad-
ministered subsequent to the receipt of final blood culture re-
sults [23]. To be categorized as adequate empirical treatment,
antimicrobial therapy had to meet the following criteria: in-
travenous administration of at least 1 antibiotic to which the
isolate expressed in vitro susceptibility that started within 2
days after the positive index blood culture had been obtained
or within 1 day if the patient had severe sepsis or septic shock.
On the basis of severity of illness and primary site of infection,
in some cases oral therapy was also considered adequate em-
pirical therapy. These cases were judged by 6 of the investigators
(H.S., S.H., C.B.-B., A.T., J.K., and M.B.), and consensus was
reached after discussion. To be categorized as adequate defin-
itive treatment, antimicrobial therapy had to meet the following
criteria: intravenous administration for at least 3 days (with
few exceptions made by the investigators) of at least 1 antibiotic
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Table 2. Results of Hospital Recruitment per
Country
This table is available in its entirety in
the online version of Clinical Infectious Diseases
Figure 2. Hospitals from 9 Western European countries that participated
in the study.
to which the isolate expressed in vitro susceptibility for a total
duration of at least 14 days and, if empirical treatment was
inadequate, adjustment of treatment on the day of the final
blood culture result [23, 24]. No antibiotic therapy or mono-
therapy with aminoglycosides, trimethoprim, fusidic acid, or
rifampicin was deemed inadequate.
For all patients in the cohort, the following covariates were
considered: MRSA prevalence among SAB episodes in the coun-
try based on European surveillance data recorded in the Euro-
pean Antimicrobial Resistance Surveillance System (EARSS) net-
work [7] dichotomized as high (110%) versus low (10%),
teaching or nonteaching hospital, age, sex, modified Charlson
comorbidity score [25], immunodeficiency status (presence of
human immunodeficiency virus or AIDS, splenectomy, immu-
nosuppressive treatment, chemotherapy of !4 weeks duration
for SAB, and solid organ or bone marrow transplantation), his-
tory of documented colonization or infection due to S. aureus
within the previous 12 months, number of hospital days before
the index blood culture was obtained (if a patient was transferred
from another hospital, the date of admission to the first hospital
was used), department at time that the index blood culture was
obtained (dichotomized as intensive care unit [ICU] vs. non-
ICU), methicillin susceptibility status of the S. aureus isolate,
source of SAB (hospital or community acquired), primary site
of infection (dichotomized as primary vs secondary SAB), and
severity of sepsis (severe sepsis or septic shock vs sepsis [26]).
Mortality was defined as in-hospital death due to any cause
within 30 days after the index blood culture was obtained.
Whether an end-of-life decision had been made was also
recorded.
To validate the quality of study data, we performed a validity
check for the recorded data in a sample of 10% of case report
forms (CRFs) in 2 randomly chosen participating hospitals per
country. The validity check consisted of 2 quality indicators:
first, we checked whether all consecutive eligible patients with
SAB during the surveillance period were included. In a face-
to-face interview, it was determined whether the number of
complete CRFs agreed with a provided list of all patients with
SAB and whether patients were correctly included or excluded.
The inclusion percentage was derived from the number of in-
cluded patients divided by the number of eligible patients. The
second quality indicator was the accuracy of data reporting on
treatment. To assess the accuracy of the collected CRFs com-
pared with the “gold standard” medical record, we established
the proportion of unknown or inappropriate data in the CRFs
for the following selected variables: date of obtaining the index
blood culture, date of definitive culture result, oxacillin sus-
ceptibility of S. aureus, starting date of first treatment, anti-
biotic(s) used as first treatment, administration of second treat-
ment within 30 days after index blood culture (and if so, the
starting date of second treatment and antibiotic(s) used as sec-
ond treatment), and outcome 30 days after the index blood
culture was obtained. We randomly selected 1, 2, or 3 CRFs
per selected hospital. The percentage of correctly recorded an-
swers was derived from the number of correctly recorded items
divided by total number of checked items.
Statistical analysis. The primary goal of this study was
independent of a specific statistical hypothesis and did not
require a sample size calculation. However, to be able to answer
the secondary research question (predictors of inadequate treat-
ment), we aimed to include 400 SAB episodes, assuming 25%
inadequate treatment and a final model containing 10 variables
of significant importance.
Bivariate analyses were performed using Fisher’s exact tests,
and Mann-Whitney U tests were performed to compare con-
tinuous variables. To analyze adequate treatment and 30-day
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Table 3. Risk Factors for Inadequate Empirical Antimicrobial Therapy and Characteristics of Patients
Covariate
Adequate treatment
(n p 240)
Inadequate treatment
(n p 94) OR (95% CI)b Pa
MRSA prevalence 110% (vs !10%)c 102 (42.7) 60 (63.8) … .001
Teaching (vs nonteaching) hospital 184 (76.7) 68 (72.3) … .40
Age, median years (IQR) 67 (52.5–78) 70 (59–81) … .08
Male (vs female) 155 (64.6) 69 (73.4) … .15
Modified Charlson comorbidity score, median value (IQR) 3.0 (1–5) 3.0 (1–5) … .13
Immunocompromised (vs nonimmunocompromised) 28 (11.7) 12 (12.8) … .85
Staphylococcus aureus history (vs no S. aureus history)
within the last 12 months 38 (15.8) 22 (23.4) … .11
Length of stay before onset of SAB, median days (IQR) 1.0 (0.0–9.0) 3.0 (1.0–14.0) 1.01 (1.00–1.03) .01
Hospital-acquired (vs community-acquired) bacteremia 106 (44.2) 52 (55.3) … .07
Secondary (vs primary) bacteremia 89 (37.1) 33 (35.1) … .80
Severe sepsis or septic shock (vs sepsis) at onset of SAB 88 (36.7) 38 (40.4) … .53
ICU hospitalization (vs non-ICU) at onset of SAB 55 (22.9) 18 (19.1) … .56
MRSA (vs MSSA) 37 (15.4) 40 (42.6) 3.73 (2.16–6.44) !.001
NOTE. Data are presented as no. (%) of patients, unless otherwise indicated. CI, confidence interval; ICU, intensive care unit; IQR,
interquartile range; MRSA, methicillin-resistant S. aureus; MSSA, methicillin-susceptible S. aureus; OR, odds ratio; SAB, Staphylococcus
aureus bacteremia.
a Results of bivariate analyses.
b Independent variables (adjusted ORs) associated with inadequate empirical antimicrobial therapy in a multivariate logistic regression
model.
c MRSA prevalence in SAB episodes in the country [7] dichotomized as high (110%) versus low (10%).
mortality rates and the different covariates contributing, we
performed a multivariate logistic regression. Kaplan-Meier sur-
vival curves were plotted for patients with MSSA versus MRSA
SAB and were compared by means of a signed log-rank test
with time to adequate treatment as an outcome.
For sensitivity analysis, multilevel logistic regression analysis
predicting adequate treatment and 30-day mortality rates was
conducted to correct for cluster effects within hospitals and
within countries. If results showed no cluster effects, we as-
sumed patient independence and only present data of the mul-
tivariate logistic regression models. Moreover, a propensity score
was added as an additional covariate to determine whether mea-
sured differences between the inadequate and adequate groups
contributed to residual confounding. To calculate a propensity
score for the probability of inadequate treatment, we used the
multivariate logistic regression model with inadequate treatment
as the dependent variable.
We used the Akaike information criterion to determine the
model with the best fit of the data (ie, the model with the
lowest Akaike information criterion value). Effect modification
was examined by using clinically important interaction terms.
Various covariates at the hospital and patient levels were
screened for colinearity, and in some cases, decisions were made
to exclude variables from the model.
Results are presented as odds ratios (ORs) with 95% con-
fidence intervals (CIs). For interpretation of the final model
results, tests of significance were 2-tailed, and was con-P .05
sidered to be statistically significant. The data were analyzed
using SPSS statistical software, version 15.0 (SPSS), and R,
version 2.8.0 (R Foundation for Statistical Computing).
RESULTS
Recruitment of hospitals. For each country, a randomly gen-
erated list of hospitals was created. In total, the 9 lists included
5291 hospitals, of which 1007 (19%) were contacted in con-
secutive order. Of these, 282 (28%) were deemed to be ineli-
gible. Of the remaining 725 hospitals, 100 (14%) consented to
participate, whereas 253 (35%) did not respond to the invi-
tation, and 366 (50%) declined to participate (Figure 1; Table
2). Of the 100 hospitals that agreed to participate, 40 (40%)
dropped out during the process of data collection.
The proportions of MRSA among SAB episodes per country
in the final cohort of 60 hospitals accurately matched the EARSS
data [7]; the only significant difference was found for Germany,
which had an incidence of MRSA of 38% in our data versus
20% in the EARSS dataset. Furthermore, the balance between
teaching and nonteaching hospitals in the complete list of hos-
pitals and our final cohort of 60 hospitals was comparable for
6 countries. For Switzerland, Denmark, and France, teaching
hospitals were overrepresented in our cohort compared with the
hospital lists (50% vs 7%, 33% vs 2%, and 67% vs 4% for
Switzerland, Denmark, and France, respectively). Figure 2 shows
the location and characteristics of the participating hospitals.
Patient characteristics. The final cohort consisted of 334
episodes of SAB: 77 (23%) were caused by MRSA, 257 (77%)
were caused by MSSA, 158 (47%) were hospital acquired (with
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Table 4. Overview of Episodes of Inadequate Empirical Antimicrobial Therapy
Variable
No. of patients
MSSA
(n p 257)
MRSA
(n p 77)
Receipt of inadequate treatment 54a 40a
Receipt of antibiotic treatment to which the pathogen was not susceptible
Overall 11 24
No treatment 5 2
Penicillin 5 2
Trimethoprim monotherapy 1
Oxacillin, penicillin, and gentamicin … 1
Other b-lactams … 12b
Other b-lactam (piperacillin–tazobactam) and antibiotic resistance (ciprofloxacin) … 2
Other b-lactam (piperacillin–tazobactam) and amikacin … 1
Intermediate resistance to antibiotic … 3c
Antibiotic resistance (ciprofloxacin) … 1
Inadequate route of administrationd 13 2
Antibiotic treatment started 2 days (1 day for patients with severe sepsis or
septic shock) after index blood culture 34 19
NOTE. MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible S. aureus.
a The total number of patients who received inadequate treatment is lower than the sum of the separate criteria, because
some patients received inadequate treatment according to 11 criterion.
b Four patients received amoxicillin–clavulanic acid, 1 received cefazolin, 3 received ceftriaxone, 1 received cefuroxime,
1 received ertapenem, and 2 received piperacillin–tazobactam.
c Two patients received teicoplanin, and 1 received vancomycin.
d Oral prescription of empirical antibiotics was deemed to be inadequate (with few exceptions, depending on severity of
illness and primary site of infection, on the basis of the opinion of the investigators).
Table 5. Overview of Episodes of Inadequate
Definitive Antimicrobial Therapy
This table is available in its entirety in
the online version of Clinical Infectious Diseases
a median length of stay before the index blood culture was
obtained of 10 days; interquartile range [IQR], 5–25 days), and
175 (53%) were community acquired. A total of 212 patients
(64%) had primary SAB (including unknown site and catheter-
associated infections), and 122 patients (37%) had another site
of infection as a source for SAB. The median patient age was
68 years (IQR, 55–79 years), and 224 patients were male (67%).
Forty-nine index blood culture samples (15%) were obtained
in the ICU, and 126 patients (38%) had severe sepsis or septic
shock (Table 3).
The overall 30-day mortality rate was 24% (80 of 334 pa-
tients died), with an end-of-life decision being made for 31 pa-
tients (39%). The median time from onset of SAB to death was
6.0 days (IQR, 2–15 days).
Inadequate antimicrobial therapy. According to the def-
inition, 94 episodes (28%) were considered to be inadequate
empirical antimicrobial therapy. These proportions were 21%
(54 of 257 cases) for MSSA and 52% (40 of 77 cases) for MRSA
( ) (Table 4). Oral therapy was considered to be adequateP ! .001
empirical therapy in 5 of 16 episodes.
According to our definitions, 114 episodes (34%) of SAB
received inadequate definitive antimicrobial therapy (Table 5).
These proportions were 30% (76 of 257) for MSSA and 49%
(38 of 77) for MRSA ( ). The intravenous-to-oralPp .002
switch of therapy within 14 days was considered to be adequate
in 25 of 29 episodes. Five days after the index blood culture
was obtained, 92% of the patients with MSSA received adequate
therapy, compared with 83% of those with MRSA ( )P ! .001
(Figure 3), although many did not receive appropriate anti-
biotics for the adequate duration: of those patients with a fol-
low-up of 14 days, 66% received antibiotics for at least 14
days.
Predictors of inadequate empirical antimicrobial therapy.
The only 2 covariates significantly associated with inadequate
empirical antimicrobial therapy were methicillin resistance
(OR, 3.7; 95% CI, 2.2–6.4) and length of stay (in days) before
SAB (OR, 1.01; 95% CI, 1.00–1.03) (Table 6). The only co-
variate that was significantly associated with inadequate defin-
itive antimicrobial therapy was methicillin resistance (OR, 2.3;
95% CI, 1.4–3.9). After excluding methicillin resistance as a
covariate (because it will be unknown at the time that the blood
culture sample is obtained), high (110%) MRSA prevalence in
the country was independently associated with inadequate em-
pirical antimicrobial therapy (OR, 2.2; 95% CI, 1.3–3.6) to-
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Figure 3. Kaplan-Meier curve with time to adequate antibiotic treatment in patients with Staphylococcus aureus bacteremia (SAB). Dotted line, methicillin-
resistant S. aureus (MRSA) bacteremias; solid line, methicillin-susceptible S. aureus (MSSA) bacteremias; plus sign, censored cases (discharged from the
hospital). The cumulative incidence of adequate antibiotic treatment over time was significantly lower among patients with MRSA-related SAB (P !
)..001
gether with length of stay (in days) before SAB (OR, 1.02; 95%
CI, 1.00–1.03).
Effect of inadequate empirical antimicrobial therapy on 30-
day mortality rates. The 30-day mortality rate was 21.3% (20
of 94 patients died) for patients receiving inadequate and 25.0%
(60 of 240 patients died) for those receiving adequate empirical
therapy within the first 2 days after onset of bacteremia. In
bivariate analysis, adequate empirical antimicrobial therapy was
not significantly associated with 30-day mortality (OR, 0.69;
95% CI, 0.36–1.33) (Table 6). Covariates that were associated
with 30-day mortality in multivariate logistic regression were
age, modified Charlson comorbidity score, the severity of illness
(defined by severe sepsis or septic shock), and ICU admission
at time of onset of SAB. The interaction term between age and
modified Charlson comorbidity score was significant and thus
retained in the final model. Both inadequate empirical anti-
microbial therapy and the presence of MRSA were not signif-
icantly associated with 30-day mortality. To adjust for clustering
effects and residual confounding due to differences between
the group that received adequate treatment and the group that
received inadequate treatment, multilevel analysis and a pro-
pensity score were added to the final regression model, re-
spectively. Both did not substantially change the effect estimates
of the models (data not shown).
Validation of data quality. Eighteen (30%) of 60 partici-
pating hospitals were randomly assigned to the quality check
of data. In these 18 hospitals, 118 of 122 eligible SAB episodes
had been included (97%). Thirty-eight of the completed 334
CRFs were randomly selected to compare 9 items with the
original patient records. In total, 282 (94%) of 300 items were
in accordance with the patient records. No statistically signif-
icant differences were found in outcomes between the sam-
pled cases and the total database.
DISCUSSION
In this study of 334 episodes of SAB in 9 Western European
countries, 28% of patients initially received inadequate anti-
microbial therapy, including 21% with MSSA bacteremia and
52% with MRSA bacteremia (even those with a severe clinical
status). Five days after the index blood culture was obtained,
92% and 83% of patients received adequate treatment for MSSA
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Table 6. Risk Factors for 30-Day Mortality and Characteristics of Patients
Covariate
Alive
(n p 254)
Death (all cause)
(n p 80) OR (95% CI)a P b
Teaching (vs nonteaching) hospital 197 (77.6) 55 (68.8) … .11
Age, median years (IQR) 66.0 (54–76.0) 74.5 (62.5–83) 1.06 (1.03–1.10) !.001
Male (vs female) 170 (66.9) 54 (67.5) … .93
Modified Charlson comorbidity score, median value (IQR) 3.0 (0–5) 4.0 (2–6) 2.09 (1.21–3.63) .001
Immunocompromised (vs nonimmunocompromised) 32 (12.6) 8 (10.0) … .53
Secondary (vs primary) bacteremia 94 (37.0) 28 (35.0) … .75
Length of stay before onset of SAB, median days (IQR) 2.0 (0–10) 2.0 (0–9.5) … .67
Hospital-acquired (vs community-acquired) bacteremia 119 (46.9) 39 (48.8) … .80
Severe sepsis or septic shock (vs sepsis) at onset of SAB 77 (30.3) 49 (61.3) 2.68 (1.52–4.75) !.001
ICU hospitalization (vs non-ICU) at onset of SAB 44 (17.3) 29 (36.3) 2.89 (1.48–5.64) !.001
Inadequate (vs adequate) empirical treatment 74 (29.1) 20 (25.0) 0.69 (0.36–1.32) .57
MRSA (vs MSSA) 57 (22.4) 20 (25.0) 0.98 (0.50–1.94) .64
Age  modified Charlson comorbidity score (interaction term)c … … 0.99 (0.98–0.999) !.001
NOTE. Data are no. (%) of patients, unless otherwise indicated. CI, confidence interval; ICU, intensive care unit; IQR, interquartile range; MRSA,
methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible S. aureus; OR, odds ratio; SAB, S. aureus bacteremia.
a Independent variables (adjusted ORs) associated with mortality in a multivariate logistic regression model.
b Results of bivariate analyses.
c Effect modification was examined by using clinically important interaction terms. The interaction term betweenageandmodifiedCharlsoncomorbidity
score was the only significant interaction and was retained in the final model.
and MRSA, respectively. Neither inadequate empirical treatment
nor methicillin resistance was associated with 30-day mortality.
These findings suggest that thousands of patients receive inad-
equate treatment for SAB in European countries and that, even
with low estimated rates of attributable mortality due to inad-
equate empirical treatment, many patients may die as a result.
This study is unique in several ways. First, it is, to our knowl-
edge, the first international study on SAB that involved the
participation of hospitals from 9 European countries. Second,
the hospitals in these countries were randomly approached for
participation. Third, the quality of the data was validated, with
94% of the checked items found to be accurate and no evidence
of selection bias of included patients. The representativeness of
the participating hospitals is further supported by the consis-
tency of MRSA prevalence in each country in our study with
the data reported by EARSS. This suggests that the results and
outcomes of this study adequately reflect the present situation
in Western Europe regarding the adequacy of antibiotic treat-
ment of patients with SAB.
Inadequate antimicrobial treatment was strongly associated
with methicillin resistance. On a country level, high MRSA prev-
alence was associated with inadequate treatment. This seems sur-
prising, because one would have expected that local guidelines
had been adapted to MRSA endemicity.
In our study, inadequate antimicrobial therapy was not as-
sociated with increased mortality rates, which contradicts some
[15–19] but not all studies [20–22]. These conflicting findings
may result from differences in methods and populations, mak-
ing generalizations difficult [23]. The obvious intuitive asso-
ciation between inadequate treatment and mortality may be
obscured by several factors. First, evidence exists that certain
b-lactam antibiotics, although assumed to be inadequate, have
some effect in treating MRSA bacteremia [27]. This could ex-
plain why 7 (9%) of 77 patients with MRSA bacteremia con-
tinued to receive b-lactam antibiotics to which the isolate ex-
pressed in vitro resistance, even after recognition of MRSA in
the blood culture results. Final results could have been over-
looked; possibly, these patients had experienced clinical im-
provement while receiving so-called inadequate treatment,
which is supported by the low 30-day mortality rate (11%) in
this subset. Second, although glycopeptides are considered to
be adequate for the treatment of MSSA bacteremia, there is
evidence that vancomycin is inferior to b-lactam antibiotics for
serious MSSA infections [28]. In our study, 13 of 257 MSSA
bacteremia episodes were treated with glycopeptide mono-
therapy, but the 30-day mortality rate in this subset was 15%.
Considering glycopeptide monotherapy as inadequate, there-
fore, would not have changed our interpretations. Third, we
adjusted for multiple covariates by using multivariable regres-
sion and propensity scoring, but there is still a possibility that
residual confounding by indication and confounding by other
than antibiotic interventions (eg, foreign body removal and
drainage of foci of infection) were insufficiently addressed. Fi-
nally, 50% of our patients had community-acquired SAB. Be-
cause the true onset of SAB is less obvious in this population,
initial adequacy of antimicrobial therapy may have less impact
on patient outcome. Restricting our analyses to hospital-ac-
quired SAB episodes, though, did not change our findings.
Our study also has several limitations. First, we did not per-
form an external validation of the microbiology data: identifi-
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cation of S. aureus and determination of antibiotic suscepti-
bilities were performed according to local protocols. Second,
30-day mortality was assessed in the hospital setting only, and
deaths occurring after hospital discharge (but still within 30
days after the index blood culture was obtained) were not in-
cluded. Thus, informative censoring could have biased our ef-
fect estimates. However, all patients (except for 1 patient with
an end-of-life decision) who were discharged from the hospital
within 30 days were categorized as having resolved SAB (ac-
cording to the physicians’ opinion), and 31 of 36 patients with
an end-of-life decision died during hospitalization. Of the re-
maining 5 patients (all of whom had unresolved SAB), only 1
was discharged within 30 days. This suggests that patients who
were discharged before 30 days after the index blood culture
had a good prognosis and that it is unlikely that incomplete
follow-up strongly biased our findings. Third, although sus-
ceptibility test results, route and duration of administration,
and time to adequate treatment were included in the definition
of adequate treatment, appropriate dosing of antibiotic treat-
ment, switching to narrow-spectrum antibiotics, and accor-
dance with local antibiotic guidelines were not [23, 24]. With
these criteria, rates of inadequate treatment would have been
even higher.
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